Small-animal PET with a s-ligand, 11C-SA4503, detects spontaneous pituitary tumors in aged rats

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1377-1383

  Ramakrishnan, Nisha K ^a   Rybczynska, Anna A ^a   Visser, Anniek K D ^a   Marosi, Krisztina ^b   Nyakas, Csaba J ^b   Kwizera, Chantal ^a   Sijbesma, Jurgen W A ^a   Elsinga, Philip H ^a   Ishiwata, Kiichi ^c   Pruim, Jan ^a   Dierckx, Rudi A J O ^a   Van Waarde, Aren ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

11C SA4503; Kinetic analysis; Sigma receptor; Small animal PET; Spontaneous pituitary tumor

Indexed keywords

CUTAMESINE C 11; RADIOPHARMACEUTICAL AGENT; SIGMA 1 OPIATE RECEPTOR; UNCLASSIFIED DRUG;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN REGION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISTRIBUTION VOLUME; DRUG DISTRIBUTION; DRUG TUMOR LEVEL; HYPOPHYSIS TUMOR; ISOTOPE LABELING; LIGAND BINDING; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; THYROID GLAND; TISSUE DISTRIBUTION;

11C-SA4503; KINETIC ANALYSIS; SIGMA RECEPTOR; SMALL-ANIMAL PET; SPONTANEOUS PITUITARY TUMOR;

AGING; ANIMALS; BRAIN; KINETICS; LIGANDS; MALE; PIPERAZINES; PITUITARY NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, WISTAR; RECEPTORS, SIGMA; TISSUE DISTRIBUTION;

EID: 84881449410     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.115931     Document Type: Article

References (37)

1. 18F]fluoro-ethyl-spiperone. Eur J Nucl Med. 1997;24:1149-1155.
2. Jane JA, Laws ER Jr. The management of non-functioning pituitary adenomas. Neurol India. 2003;51:461-465.
3. Fougner SL, Lekva T, Borota OC, Hald JK, Bollerslev J, Berg JP. The expression of E-cadherin in somatotroph pituitary adenomas is related totumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab. 2010;95:2334-2342.
4. Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors.QJ Nucl Med Mol Imaging. 2004;48:150-163.
5. Lafferty AR, Chrousos GP. Pituitary tumors in children and adolescents. J Clin Endocrinol Metab. 1999;84:4317-4323.
6. Monson JP. The epidemiology of endocrine tumours. Endocr Relat Cancer. 2000;7:29-36.
7. Hyun SH, Choi JY, Lee KH, Choe YS, Kim BT. Incidental focal 18F-FDG uptake in the pituitary gland: clinical significance and differential diagnostic criteria. J Nucl Med. 2011;52:547-550.
8. Heaney AP. Clinical review: pituitary carcinoma-difficult diagnosis and treatment. J Clin Endocrinol Metab. 2011;96:3649-3660.
9. Bergström M, Muhr C, Lundberg PO, Langstrom B. PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med. 1991;32:610-615.
10. Stanley T, Prabhakaran R, Misra M. Sellar and pituitary tumors in children. In: Brooke S, Biller BMK, eds. Contemporary Endocrinology: Diagnosis and Management of Pituitary Disorders. Totowa, NJ: Human Press Inc.; 2008:412.
11. Buchfelder M, Schlaffer SM. Modern imaging of pituitary adenomas. Front Horm Res. 2010;38:109-120.
12. Drevelegas A, ed. Imaging of Brain Tumors with Histological Correlations. Berlin, Germany: Springer; 2011:327-333.
13. Jeong SY, Lee SW, Lee HJ, et al. Incidental pituitary uptake on whole-body 18FFDGPET/ CT: amulticentre study. Eur J NuclMedMol Imaging. 2010;37:2334-2343.
14. Ryu SI, Tafti BA, Skirboll SL. Pituitary adenomas can appear as hypermetabolic lesions in 18F-FDG PET imaging. J Neuroimaging. 2010;20:393-396.
15. Ryu JS, Um JW, Min BW. Inflammatory pseudotumour of the spleen: the findings on F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). ANZ J Surg. 2010;80:650-652.
16. Chiewvit S, Chiewvit P, Pusuwan P, Sriussadaporn S, Ratanamart V. Somatostatin receptor tumor imaging (Tc-99m P829) in pituitary adenoma. J Med Assoc Thai. 1999;82:1208-1213.
17. van Waarde A, Rybczynska AA, Ramakrishnan N, Ishiwata K, Elsinga PH, Dierckx RA. Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. Curr Pharm Des. 2010;16:3519-3537.
18. Kekuda R, Prasad PD, Fei YJ, Leibach FH, Ganapathy V. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem Biophys Res Commun. 1996;229:553-558.
19. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca21 signaling and cell survival. Cell. 2007;131:596-610.
20. Xu J, Zeng C, Chu W, et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun. 2011;2:380.
21. Wolfe SA, Culp SG, De Souza EB. Sigma-receptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. Endocrinology. 1989;124:1160-1172.
22. 11C-SA4503: a feasibility study. J Nucl Med. 2004;45:1939-1945.
23. Mishina M, Ohyama M, Ishii K, et al. Low density of sigma1 receptors in early Alzheimer's disease. Ann Nucl Med. 2008;22:151-156.
24. MishinaM, Ishiwata K, Ishii K, et al. Function of sigma1 receptors in Parkinson's disease. Acta Neurol Scand. 2005;112:103-107.
25. van Waarde A, Shiba K, de Jong JR, Ishiwata K, Dierckx RA, Elsinga PH. Rapid reduction of sigma1-receptor binding and 18F-FDG uptake in rat gliomas after in vivo treatment with doxorubicin. J Nucl Med. 2007;48:1320-1326.
26. van Waarde A, Jager PL, Ishiwata K, Dierckx RA, Elsinga PH. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med. 2006;47:150-154.
27. 11Cand 18F-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl]-4-(3- phenylpropyl)piperazines as sigma receptor ligands for positron emission tomography studies. Nucl Med Biol. 2003;30:273-284.
28. Weber K, Razinger T, Hardisty JF, et al. Differences in rat models used in routine toxicity studies. Int J Toxicol. 2011;30:162-173.
29. 11C]SA4503. Neuroimage. 2007;35:1-8.
30. Schweinhardt P, Fransson P, Olson L, Spenger C, Andersson JL. A template for spatial normalisation of MR images of the rat brain. J Neurosci Methods. 2003;129:105-113.
31. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539.
32. Schaeffer M, Hodson DJ, Lafont C, Mollard P. Functional importance of blood flow dynamics and partial oxygen pressure in the anterior pituitary. Eur J Neurosci. 2010;32:2087-2095.
33. Bem WT, Thomas GE, Mamone JY, et al. Overexpression of sigma receptors in nonneural human tumors. Cancer Res. 1991;51:6558-6562.
34. Thomas GE, Szucs M, Mamone JY, et al. Sigma and opioid receptors in human brain tumors. Life Sci. 1990;46:1279-1286.
35. Spruce BA, Campbell LA, McTavish N, et al. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and selfreliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 2004;64:4875-4886.
36. Simony-Lafontaine J, Esslimani M, Bribes E, et al. Immunocytochemical assessment of sigma-1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors. Br J Cancer. 2000;82:1958-1966.
37. Sambaziotis D, Kapranos N, Kontogeorgos G. Correlation of bcl-2 and bax with apoptosis in human pituitary adenomas. Pituitary. 2003;6:127-133.